Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
Go back to Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan| Merck & Co. (NYSE: MRK) | Delayed: 148.46 -0.32 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.78 | 52 Week High | $65.46 | |||
| Open | $147.65 | 52 Week Low | $47.97 | |||
| Day High | $149.19 | P/E | 100.99 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 3,398,911 | |||||
